Law360, New York (October 14, 2011, 4:32 PM EDT) -- A New York federal judge on Friday shot down a move by the Mathilda and Terence Kennedy Institute of Rheumatology Trust to dismiss Abbott Biotechnology Ltd.'s suit over the institute's patent allegedly covering the anti-inflammatory drug Humira.
Abbott, which produces and markets Humira, has a licensing agreement with Mathilda that allows Abbott to market the use of Humira in combination with the antimetabolite and antifolate drug methotrexate, the suit says. This drug cocktail is covered by Mathilda's U.S. Patent No. 6,270,766, according to the suit.
While that patent is set to expire in October 2012, Mathilda informed Abbott in a January...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!